Last reviewed · How we verify

larotaxel (RPR109881, XRP9881)

Sanofi · Phase 3 active Small molecule

larotaxel (RPR109881, XRP9881) is a Taxane (microtubule stabilizer) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Metastatic breast cancer, Non-small cell lung cancer, Gastric cancer.

Larotaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.

Larotaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Gastric cancer.

At a glance

Generic namelarotaxel (RPR109881, XRP9881)
SponsorSanofi
Drug classTaxane (microtubule stabilizer)
Targetβ-tubulin
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

As a third-generation taxane derivative, larotaxel stabilizes microtubules by binding to β-tubulin, similar to paclitaxel and docetaxel but with improved pharmacokinetic properties and potentially reduced peripheral neuropathy. This mechanism disrupts mitotic spindle formation, causing G2/M phase arrest and triggering apoptosis in rapidly dividing cancer cells. The drug was designed to have better tissue penetration and lower neurotoxicity compared to earlier taxanes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about larotaxel (RPR109881, XRP9881)

What is larotaxel (RPR109881, XRP9881)?

larotaxel (RPR109881, XRP9881) is a Taxane (microtubule stabilizer) drug developed by Sanofi, indicated for Metastatic breast cancer, Non-small cell lung cancer, Gastric cancer.

How does larotaxel (RPR109881, XRP9881) work?

Larotaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.

What is larotaxel (RPR109881, XRP9881) used for?

larotaxel (RPR109881, XRP9881) is indicated for Metastatic breast cancer, Non-small cell lung cancer, Gastric cancer.

Who makes larotaxel (RPR109881, XRP9881)?

larotaxel (RPR109881, XRP9881) is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is larotaxel (RPR109881, XRP9881) in?

larotaxel (RPR109881, XRP9881) belongs to the Taxane (microtubule stabilizer) class. See all Taxane (microtubule stabilizer) drugs at /class/taxane-microtubule-stabilizer.

What development phase is larotaxel (RPR109881, XRP9881) in?

larotaxel (RPR109881, XRP9881) is in Phase 3.

What are the side effects of larotaxel (RPR109881, XRP9881)?

Common side effects of larotaxel (RPR109881, XRP9881) include Neutropenia, Peripheral neuropathy, Anemia, Fatigue, Nausea/vomiting, Alopecia.

What does larotaxel (RPR109881, XRP9881) target?

larotaxel (RPR109881, XRP9881) targets β-tubulin and is a Taxane (microtubule stabilizer).

Related